Icelandic generic drug major Actavis has entered into an exclusive collaboration with USA-based privately-held Sagent Pharmaceuticals to develop and market a select group of specialty injectable medications. Under the terms of the deal, financial details of which were not disclosed, Actavis will develop, obtain Food and Drug Administration approval and supply the products, which Sagent will market in the USA.
"Actavis' impressive injectable pipeline, substantial development and supply capabilities and excellent record of execution make Actavis an outstanding partner for Sagent," said Jeffrey Yordon, Sagent's chief executive, founder and chairman, noting that "this collaboration complements Sagent's strategy by quickly adding products to our marketed portfolio and we look forward to working with Actavis to expand our collective portfolio."
Doug Boothe, chief executive of Actavis' US unit, said the strategic collaboration with Sagent will enable consumers in the USA to benefit from the company's global expertise in developing and manufacturing specialty injectable products. "By combining our injectable
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze